Topic / Pathology
- ALS
- Phase 2
Objectives
To assess the effect of NX210c on blood neurofilament light chain (NfL) or on a blood and cerebrospinal fluid (CSF) biomarker of BBB integrity at 6-week follow-up.
Learn more about : https://clinicaltrials.gov/study/NCT06365216
Sponsor
AXOLTIS Pharma
Investigator
National coordinator : Dr Emilien Bernard
Partnership(s) with patients association(s)
-
ARSLA - https://www.arsla.org
Critères d'inclusion
- Aged ≥ 18 years, inclusive at screening.
- Patients diagnosed as having possible, probable, probable laboratory-supported, or definite ALS according to El Escorial Revised criteria.
- King's Clinical Staging Stage ≤3, disease duration of ≤ 36 calendar months
Critères de non-inclusion
- Patients with any cognitive or psychological disorder, intellectual disability or other significant impairment that would result in an inability to understand and sign the informed consent.
- History of any clinically significant or unstable medical, neurological, psychiatric condition, disorder or disease (other than ALS) or social circumstances that, based on the investigator's judgment, would interfere with the conduct of the study or pose a risk to the patient if they were to participate.
Status
Follow-Up (recruiting ended)
